Welcome to our dedicated page for Atara Biotherape news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherape stock.
Atara Biotherapeutics (NASDAQ: ATRA) is a leading innovator in cellular immunotherapy, developing transformative treatments for cancer and autoimmune diseases. This news hub provides investors and healthcare professionals with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely updates on T-cell therapy advancements, including CAR T platform developments and collaboration progress with Memorial Sloan Kettering Cancer Center. Our curated collection features press releases about product candidates in oncology and autoimmune research, financial disclosures, and manufacturing updates.
Key content includes analysis of Phase 1-3 trial outcomes, FDA communications regarding allogeneic therapies, and licensing agreements supporting ATRA's pipeline development. Bookmark this page for direct access to primary source materials and objective reporting on the company's progress in addressing unmet medical needs through innovative immunotherapies.
Atara Biotherapeutics (NASDAQ: ATRA) has granted 7,200 restricted stock units to two new employees, approved by its Compensation Committee under the 2018 Inducement Plan. The grant date was November 1, 2022. The stock units vest over four years, with 25% vesting after the first anniversary and the remainder vesting quarterly. This action complies with Nasdaq Listing Rule 5635(c)(4). Atara focuses on T-cell immunotherapy, developing therapies for cancer and autoimmune diseases, and is advancing multiple programs targeting serious diseases.
Atara Biotherapeutics (NASDAQ: ATRA) will announce its third quarter 2022 financial results on November 8, 2022, after market close. A live conference call and webcast will follow at 4:30 p.m. EST, where the company will discuss financial results and corporate updates. Atara is a leader in T-cell immunotherapy, focusing on allogeneic Epstein-Barr virus (EBV) T-cell platforms for treating cancer and autoimmune diseases. The company is advancing multiple therapies, with a promising pipeline including tab-cel, currently in Phase 3 development for EBV-driven post-transplant lymphoproliferative disease.
Atara Biotherapeutics (ATRA) announced promising results regarding ATA188, targeting progressive multiple sclerosis (MS), with data presented at the ECTRIMS congress. In an open-label extension study, 29% of patients (7 of 24) achieved confirmed disability improvement (CDI) over 46 months. Longitudinal MRI analysis indicates less brain atrophy and potential remyelination linked to ATA188 treatment. The therapy remains well tolerated with no severe adverse effects reported. Further data will be presented at the congress on October 26, highlighting ATA188's potential impact on MS treatment.
Atara Biotherapeutics (NASDAQ: ATRA) and Pierre Fabre announced a positive opinion from the CHMP recommending the approval of EbvalloTM (tabelecleucel) for treating relapsed or refractory EBV+ PTLD in patients aged two and older. This decision is based on the pivotal Phase 3 ALLELE study, demonstrating a favorable risk-benefit profile. The European Commission's approval is expected in Q4 2022. Ebvallo represents a first-in-class allogeneic T-cell therapy, addressing a significant unmet need in a rare and aggressive cancer.
Atara Biotherapeutics (NASDAQ: ATRA) announced the grant of 8,000 restricted stock units to a newly hired employee. This stock award, approved by Atara's Compensation Committee, is part of the 2018 Inducement Plan, dated October 3, 2022. The units will vest over four years, with 25% vesting after the first year and the remaining in quarterly installments, contingent on ongoing employment. Atara continues to develop its T-cell immunotherapy platform aimed at treating serious diseases, including EBV-driven conditions.
Atara Biotherapeutics (NASDAQ: ATRA) has amended its collaboration agreement with Pierre Fabre, which includes a milestone payment of
Atara Biotherapeutics (NASDAQ: ATRA) announced participation by CEO Pascal Touchon in a cell therapy panel at the Citigroup 17th Annual Biopharma Conference on September 7, 2022, at 6:40 a.m. PDT. The event will be accessible via a live webcast on the company's website, with an archived version available for 30 days post-event. Atara specializes in T-cell immunotherapy, focusing on EBV T-cell platforms to tackle cancer and autoimmune diseases. Their lead program is in Phase 3 development for EBV+ post-transplant lymphoproliferative disease.
Atara Biotherapeutics (ATRA) has reported its Q2 2022 financial results, achieving cash reserves of $331.3 million, an increase from $301.8 million in Q1 2022. The company plans to reduce its annual cash burn by over 20%, extending its cash runway into Q1 2024. Positive developments include FDA's recommended pathway for tab-cel's BLA filing without new trials and completion of the ATA188 Phase 2 EMBOLD study Interim Analysis. However, the termination of the Bayer collaboration will significantly reduce future revenues.
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has granted 82,756 restricted stock units and stock options for 98,701 shares to newly hired employees as part of its 2018 Inducement Plan, effective August 1, 2022. The stock units vest over four years, and the options have a ten-year term with an exercise price of $2.85 per share. This grant complies with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new staff. Atara is focused on T-cell immunotherapy and has multiple programs in clinical development targeting serious diseases.
Atara Biotherapeutics (Nasdaq: ATRA) announced that its CEO, Pascal Touchon, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 9:00 a.m. PDT. The presentation will focus on the company's innovative allogeneic Epstein-Barr virus (EBV) T-cell platform aimed at treating cancer and autoimmune diseases. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event. Atara is advancing several therapies, including tab-cel® for EBV+ PTLD and ATA188 for multiple sclerosis.
FAQ
What is the current stock price of Atara Biotherape (ATRA)?
What is the market cap of Atara Biotherape (ATRA)?
